

TRUCHECK CANCER early detection:

A simple blood test that can **detect** 70 forms of cancer at a very **early stage**.



The Trucheck test by Datar Cancer Genetics is a new blood-based test for multi-cancer detection. This test can detect more than 70 different types of tumors and requires only a 25 ml blood sample.

Ideal as part of an annual health check-up, this test will help you determine if you currently have cancer (even at an early stage) and, if so, identify where the tumors are located for prompt treatment.

Diagnosing cancer at an early stage is crucial to ensuring the success of treatments, reducing side effects, and improving the chances of survival.



WHAT IS THE **Trucheck test**?

The TruCheck[™] early cancer screening blood test is a blood test that revolutionizes the ability to detect cancer in its early stages.

A non-invasive procedure, this test requires a simple blood draw. It is the only available test to check for the presence of circulating tumor cells (CTCs), detecting even the smallest existence of cancer from a small blood sample.

Very precise, it not only identifies whether you have CTCs, but also where they come from. This means you know where the primary tumor is in your body, which speeds up diagnosis and treatment, and allows doctors to focus treatment on the required areas.

We offer it as a standalone test and recommend that it be added to your annual health check-up.

It does not replace more specific tests for particular cancers, but often identifies them at an earlier stage and allows for quicker and more effective action.

The TruCheck test has received the **Breakthrough Designation**, which is **granted by the FDA** to innovative therapies. This is a priority status given by the US Food and Drug Administration to a medical device that is likely to provide a significant therapeutic advance.

> THE TEST HAS ALL THE NECESSARY MAR-KET AUTHORIZATIONS, INCLUDING CE AND FDA APPROVALS.

* During tumor development, some cancer cells can detach from solid tumors and infiltrate the bloodstream. These are circulating tumor cells (CTCs). Tumor cells will also die, disintegrate, and release fragments of their genetic material, circulating tumor DNA (ctDNA), into the blood.

WHAT IS THE **process**?


If you are eligible for the test (over 35 years old, have not had cancer, etc.), we will send you a test kit and you will need to have a blood sample taken at a laboratory of your choice.

The blood tubes will then need to be sent to our laboratory via DHL with the prepaid return envelope.

The results will be sent back to us within 2/3 weeks of receiving your samples. We will organize a call together to discuss the results with you and consider, if necessary, a follow-up protocol.

HOW IS THIS TEST revolutionary?

Launched in the UK at the end of 2022 after rigorous clinical trials, this test is brand new in the diagnostic screening industry. It is the only available test to check for the presence of circulating tumor cells (CTCs), detecting even the smallest existence of cancer from a small blood sample.



Even cancers at an early stage are reliably detected.

WHAT TYPES OF CANCER CAN TRUCHECK DETECT?

Our test can identify a wide range of solid organ cancers (cancers that affect organs rather than blood), including:

- > Melanoma
- Head and neck
- > Mesothelioma
- > Urinary tract
- > Gynecological
- Prostate
- > Thymus

- > Adrenal
- > Central nervous system
- > Breast
- > Liver
- Biliary tract
- > Gastrointestinal
- Soft tissues

- > Osteosarcomas
- > Salivary gland
- > Thyroid
- > Lung
- > And many more

ADENOCARCINOMA

(SA: salivary duct, thyroid, breast, lung, esophagus, stomach, duodenum, jejunum, ileum, colon, rectum, pancreas, gallbladder, bile ducts, liver, ovary, prostate, uterus)

SQUAMOUS CELL CARCINOMA

(SCC; Oral mucosa, hard palate, larynx, lip, oral cavity, paranasal sinus, pharynx, pyriform fossa, retromolar trigone, soft palate, tongue, tonsil, esophagus, lung, penis, cervix, vulva, vagina, anorectal, skin)

ADENOSQUAMOUS CARCINOMA

(ASC: esophagus, lung)

NEUROENDOCRINE

(NET: lung, esophagus, duodenum, jejunum, ileum, thymus, adrenal, pancreas, prostate, colon, rectum)

RENAL CELL CARCINOMA

(RCC: kidney)

TRANSITIONAL CELL CARCINOMA

(TCC: bladder, renal pelvis, ureter)

GASTROINTESTINAL STROMAL TUMORS

(GIST: stomach, duodenum, ileum, jejunum, colon, rectum)

MELANOMAS

(cutaneous, mucosal)

MESOTHELIOMA

(pleural, peritoneal)

SARCOMAS

(carcinosarcoma, chondrosarcoma, leiomyosarcoma, osteosarcoma, liposarcoma)

LUNG

GLIOMA

IN THE CASE OF BLOOD OR LYM-PHATIC SYSTEM CANCER

Trucheck cannot detect blood or lymphatic system cancers, as only solid organ cancers produce circulating tumor cells.

CANCER in France:

In 2023, more than 450,000 new cases of cancer were diagnosed in France. It is estimated that 3.8 million people are living in France today with a cancer diagnosis.

Currently, nearly half of the people are diagnosed after the cancer has spread, which leads to more intensive and expensive treatments, associated with a higher risk of side effects.



FREQUENTLY ASKED QUESTIONS

WHAT HAPPENS IF MY results are «positive»:

A positive result means that CTCs have been found in your blood. The test results will indicate the location of the type of cancer with high precision.

This means that we can tell you where the cancer started to develop.

In case of a positive result, a specialist doctor will personally call you to discuss your results and what they mean. A personalized patient journey is planned, and a 2nd control test will be offered to you free of charge.

DOES A «NEGATIVE» RESULT MEAN that I am «completely» free of cancer:

A negative result means that at the time of the test, there were no detectable cancer cells for the cancers included in the test, circulating in your blood. This does not mean that you will never develop cancer. For all cancers not covered by the test, no conclusion should be drawn from a negative result.

WHAT IS THE sensitivity of the test:

Sensitivity is the ability to correctly identify people with cancer. All TruCheck tests detect early signs of cancer in at least 88% of cases. Thus, the test will correctly identify at least 88 out of 100 people showing early signs of cancer.

WHAT IS THE specificity of the test:

Specificity is the ability to correctly identify people who do not have cancer. All TruCheck tests have a specificity of 99%. Thus, the test will correctly identify 99 out of 100 people without cancer. This means that you have a low probability of receiving a falsely positive result and undergoing unnecessary medical procedures.

ARE THERE ANY RESTRICTIONS ON people who can take this test:

Some clinical requirements must be met in order to be eligible for this test. Before you register, a pre-consultation call with our doctor will be arranged.

TO TAKE THIS TEST, YOU MUST:

- Be aged 40 or older. (People aged 35 to 40 are accepted provided they are considered high-risk, please inquire)
- Currently have no symptoms of cancer. If you have any suspicious symptoms, you should urgently consult your general practitioner.
- Never have received a diagnosis of cancer, of any kind.
- > Never have received treatment for any type of cancer.
- Not have any current clinical or radiological suspicion of cancer.
- Not receive a blood transfusion within 72 hours prior to your blood draw appointment.

HOW OFTEN SHOULD I take this test:

As this early cancer screening test is non-invasive, there is no downside to frequent testing. However, we advise taking this test every 12 months as part of an annual comprehensive health check-up process.

NOTES

- TruCheck detects the existence of cancers, not the possibility of cancers.
- Conventional means of cancer detection (mammography, colonoscopy, etc.) should sti be prioritized.
- A negative response to this test does not mean that you are free from any possibility of getting cancer.
- TruCheck is not a substitute for a medical diagnosis or treatment.

PRICE: €1,595 INCLUDING VAT



Call us to schedule a pre-consultation 00331 89 27 09 67

WHO ARE WE?



KENSINGTON CLINIC – Body Checkup:

Body Checkup and Kensington International Clinic: a team of 35 passionate doctors.

Our clinic located in central London (Gastrointestinal center of excellence) has 35 specialists in microbiota, gastroenterology, endocrinology, dietetics, naturopathy, anti-aging general practitioners.

In partnership with leading European and American laboratories, checkups have been developed to prevent and act against the early signs of disease.

DATAR MONDE - FDA Datar Europe:

Datar Cancer Genetics is a global research and applications company in molecular oncology specializing in non-invasive technologies to improve cancer detection, treatment, and management. The company's facilities are accredited by NABL, ISO, CAP, CLIA.

With nearly 300 employees, Datar has laboratories in the UK and India, an in-house bioinformatics team, and a comprehensive database that allows for reports to be produced according to the latest scientific standards.





Get the care you need, in the language you speak. Consultations available in English, French, German, Arabic, and Spanish*.

Kensington International



2 North Terrace South Kensington London SW3 2BA

France: +331 89 27 09 67 UK: +33(0) 020 7589 9321

contact@bodycheckup.com

www.bodycheckup.com